Nature Communications (Dec 2021)
Depletion of central memory CD8+ T cells might impede the antitumor therapeutic effect of Mogamulizumab
- Yuka Maeda,
- Hisashi Wada,
- Daisuke Sugiyama,
- Takuro Saito,
- Takuma Irie,
- Kota Itahashi,
- Kodai Minoura,
- Susumu Suzuki,
- Takashi Kojima,
- Kazuhiro Kakimi,
- Jun Nakajima,
- Takeru Funakoshi,
- Shinsuke Iida,
- Mikio Oka,
- Teppei Shimamura,
- Toshihiko Doi,
- Yuichiro Doki,
- Eiichi Nakayama,
- Ryuzo Ueda,
- Hiroyoshi Nishikawa
Affiliations
- Yuka Maeda
- Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center
- Hisashi Wada
- Department of Clinical Research in Tumor Immunology, Osaka University Graduate School of Medicine
- Daisuke Sugiyama
- Department of Immunology, Nagoya University Graduate School of Medicine
- Takuro Saito
- Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine
- Takuma Irie
- Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center
- Kota Itahashi
- Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center
- Kodai Minoura
- Department of Systems Biology, Nagoya University Graduate School of Medicine
- Susumu Suzuki
- Department of Tumor Immunology, Aichi Medical University
- Takashi Kojima
- Department of Gastrointestinal Oncology, National Cancer Center Hospital East
- Kazuhiro Kakimi
- Department of Immunotherapeutics, The University of Tokyo Hospital
- Jun Nakajima
- Department of Thoracic Surgery, Graduate School of Medicine, The University of Tokyo
- Takeru Funakoshi
- Department of Dermatology, Keio University School of Medicine
- Shinsuke Iida
- Department of Hematology and Oncology, Nagoya City University Institute of Medical and Pharmaceutical Sciences
- Mikio Oka
- Department of Respiratory Medicine, Kawasaki Medical School
- Teppei Shimamura
- Department of Systems Biology, Nagoya University Graduate School of Medicine
- Toshihiko Doi
- Department of Gastrointestinal Oncology, National Cancer Center Hospital East
- Yuichiro Doki
- Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine
- Eiichi Nakayama
- Faculty of Health and Welfare, Kawasaki University of Medical Welfare
- Ryuzo Ueda
- Department of Tumor Immunology, Aichi Medical University
- Hiroyoshi Nishikawa
- Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center
- DOI
- https://doi.org/10.1038/s41467-021-27574-0
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 13
Abstract
Elimination of regulatory T cells via the anti-CCR4 monoclonal antibody, mogamulizumab, is expected to augment anti-tumour immune response. Authors show here that although regulatory T cell targeting is successful, clinical improvement remains minimal in patients with solid tumours due to concomitant and unintended depletion of central memory CD8+ T cells.
